Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Could skipping breakfast help fight uterine cancer?

NCT ID NCT07622901

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 15, 2026 · Updated 2 times

Summary

This study looks at whether it is safe for women with endometrial cancer to fast overnight before their surgery. Many women with this cancer have high blood sugar and inflammation, which may help the cancer grow. The study will check if fasting is doable and liked by patients, and if it improves health markers like blood sugar and insulin levels. About 42 women will take part.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 42 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2026

Expected to finish

Feb 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Women 18 years of age or older. 2. Able to provide consent. 3. Able to read/understand English, Spanish or Haitian Creole. 4. Have a diagnosis of Type I (low-grade) endometrial cancer at any stage, histologically confirmed prior to the start of the intervention. 5. Planned minimally invasive surgical treatment (laparoscopy or robotic approach to hysterectomy). 6. Approval to participate from treating oncologist, confirmed via email or in writing. 7. Eastern Cooperative Oncology Group (ECOG) Performance status grade 0-2. 8. Surgeries must be at one of the following institutions: 1. Sylvester Comprehensive Cancer Center 2. University of Miami Hospital (UHealth) Tower 9. Internet access on a smart phone, tablet, or computer. 10. Agree to be randomly assigned to any study group. Exclusion Criteria: 1. Women less than 18 years of age. 2. Unable to provide consent. 3. Unable to read/understand English or Spanish. 4. History of prior hysterectomy. 5. Any contraindication for prolonged overnight fasting of 13 hours or exercising as determined by a physician. 6. Engaging in structured fasting consistently (equal to or more than 50% of the time) for \>12 hours/night. 7. Presence of a severe medical or psychiatric condition or medication that would preclude participation of the study intervention, unstable cardiac disease. 8. Diagnosis of diabetes treated with insulin, metformin, sulfonylureas, or Glucagon-like peptide-1 (GLP-1) agonist medications. 9. Recent history of a clinical eating disorder as determined by self-report, medical history, or clinical judgement. Participants with a history of an eating disorder that is well-managed and in sustained remission may be eligible, subject to investigator discretion. 10. Women for whom definitive hysterectomy is not planned for treatment of their endometrial cancer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Endometrial cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • University of Miami

    RECRUITING

    Miami, Florida, 33136, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.